tiprankstipranks
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
US Market
Want to see PRAX full AI Analyst Report?

Praxis Precision Medicines (PRAX) Stock Forecast & Price Target

978 Followers
See the Price Targets and Ratings of:

PRAX Analyst Ratings

Strong Buy
16Ratings
Strong Buy
14 Buy
1 Hold
1 Sell
Based on 16 analysts giving stock ratings to
Praxis
Precision Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRAX Stock 12 Month Forecast

Average Price Target

$625.31
▲(82.57% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $625.31 with a high forecast of $1,245.00 and a low forecast of $130.00. The average price target represents a 82.57% change from the last price of $342.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","337":"$337","640":"$640","943":"$943","1246":"$1,246"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":625.3125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$625.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,337,640,943,1246],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,319.28,390.48923076923074,461.6984615384615,532.9076923076923,604.1169230769231,675.3261538461538,746.5353846153846,817.7446153846154,888.9538461538461,960.1630769230769,1031.3723076923077,1102.5815384615385,1173.7907692307692,{"y":1245,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,319.28,342.8209615384615,366.36192307692306,389.9028846153846,413.44384615384615,436.9848076923077,460.52576923076924,484.06673076923073,507.60769230769233,531.1486538461538,554.6896153846154,578.2305769230769,601.7715384615385,{"y":625.3125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,319.28,304.71999999999997,290.15999999999997,275.59999999999997,261.03999999999996,246.47999999999996,231.92,217.35999999999999,202.79999999999998,188.23999999999998,173.67999999999998,159.11999999999998,144.56,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":309.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.59,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,245Average Price Target$625.31Lowest Price Target$130.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on PRAX
LifeSci Capital
LifeSci Capital
$545$567
Buy
65.55%
Upside
Reiterated
04/25/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX) and Moderna (NASDAQ: MRNA)
JonesTrading Analyst forecast on PRAX
JonesTrading
JonesTrading
$441
Buy
28.76%
Upside
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (NASDAQ: ORKA) and Praxis Precision Medicines (NASDAQ: PRAX)
Wells Fargo Analyst forecast on PRAX
Wells Fargo
Wells Fargo
$305
Hold
-10.95%
Downside
Reiterated
04/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding (Other OTC: RHHBY), Praxis Precision Medicines (NASDAQ: PRAX) and SAB Biotherapeutics (NASDAQ: SABS)
TD Cowen Analyst forecast on PRAX
TD Cowen
TD Cowen
$554
Buy
61.75%
Upside
Reiterated
04/21/26
Analysts Conflicted on These Healthcare Names: Molina Healthcare (NYSE: MOH), Boston Scientific (NYSE: BSX) and Praxis Precision Medicines (NASDAQ: PRAX)
Piper Sandler Analyst forecast on PRAX
Piper Sandler
Piper Sandler
$1,200
Buy
250.36%
Upside
Reiterated
04/21/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Intuitive Surgical (NASDAQ: ISRG) and Praxis Precision Medicines (NASDAQ: PRAX)
Deutsche Bank  Analyst forecast on PRAX
Deutsche Bank
Deutsche Bank
$412$437
Buy
27.59%
Upside
Reiterated
04/15/26
Praxis Precision price target raised to $437 from $412 at Deutsche BankPraxis Precision price target raised to $437 from $412 at Deutsche Bank
Needham Analyst forecast on PRAX
Needham
Needham
$510
Buy
48.91%
Upside
Reiterated
04/14/26
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Oncology Institute (TOI)
Raymond James Analyst forecast on PRAX
Raymond James
Raymond James
$815
Buy
137.96%
Upside
Initiated
04/08/26
Praxis Precision initiated with a Strong Buy at Raymond JamesPraxis Precision initiated with a Strong Buy at Raymond James
H.C. Wainwright Analyst forecast on PRAX
H.C. Wainwright
H.C. Wainwright
$1,245
Buy
263.50%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Adagene (NASDAQ: ADAG), Caribou Biosciences (NASDAQ: CRBU) and Praxis Precision Medicines (NASDAQ: PRAX)
Wolfe Research Analyst forecast on PRAX
Wolfe Research
Wolfe Research
$500
Buy
45.99%
Upside
Reiterated
04/06/26
Praxis: EMBRAVE Data Validate Elsunersen and De‑Risk Pipeline, Supporting Buy Rating on Favorable Risk‑Reward
Guggenheim Analyst forecast on PRAX
Guggenheim
Guggenheim
$800
Buy
133.58%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), PepGen Inc. (NASDAQ: PEPG) and Omeros (NASDAQ: OMER)
Jefferies Analyst forecast on PRAX
Jefferies
Jefferies
$525
Buy
53.28%
Upside
Reiterated
03/31/26
Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
Truist Financial Analyst forecast on PRAX
Truist Financial
Truist Financial
$700
Buy
104.38%
Upside
Reiterated
03/12/26
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (NASDAQ: SPRY), BillionToOne, Inc. Class A (NASDAQ: BLLN) and Praxis Precision Medicines (NASDAQ: PRAX)
Wedbush
$95$130
Sell
-62.04%
Downside
Reiterated
02/20/26
Analysts Conflicted on These Healthcare Names: US Physical Therapy (NYSE: USPH), Travere Therapeutics (NASDAQ: TVTX) and Praxis Precision Medicines (NASDAQ: PRAX)
Robert W. Baird Analyst forecast on PRAX
Robert W. Baird
Robert W. Baird
$275$433
Buy
26.42%
Upside
Reiterated
02/20/26
Praxis Precision price target raised to $433 from $275 at BairdPraxis Precision price target raised to $433 from $275 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on PRAX
LifeSci Capital
LifeSci Capital
$545$567
Buy
65.55%
Upside
Reiterated
04/25/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX) and Moderna (NASDAQ: MRNA)
JonesTrading Analyst forecast on PRAX
JonesTrading
JonesTrading
$441
Buy
28.76%
Upside
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (NASDAQ: ORKA) and Praxis Precision Medicines (NASDAQ: PRAX)
Wells Fargo Analyst forecast on PRAX
Wells Fargo
Wells Fargo
$305
Hold
-10.95%
Downside
Reiterated
04/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding (Other OTC: RHHBY), Praxis Precision Medicines (NASDAQ: PRAX) and SAB Biotherapeutics (NASDAQ: SABS)
TD Cowen Analyst forecast on PRAX
TD Cowen
TD Cowen
$554
Buy
61.75%
Upside
Reiterated
04/21/26
Analysts Conflicted on These Healthcare Names: Molina Healthcare (NYSE: MOH), Boston Scientific (NYSE: BSX) and Praxis Precision Medicines (NASDAQ: PRAX)
Piper Sandler Analyst forecast on PRAX
Piper Sandler
Piper Sandler
$1,200
Buy
250.36%
Upside
Reiterated
04/21/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Intuitive Surgical (NASDAQ: ISRG) and Praxis Precision Medicines (NASDAQ: PRAX)
Deutsche Bank  Analyst forecast on PRAX
Deutsche Bank
Deutsche Bank
$412$437
Buy
27.59%
Upside
Reiterated
04/15/26
Praxis Precision price target raised to $437 from $412 at Deutsche BankPraxis Precision price target raised to $437 from $412 at Deutsche Bank
Needham Analyst forecast on PRAX
Needham
Needham
$510
Buy
48.91%
Upside
Reiterated
04/14/26
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Oncology Institute (TOI)
Raymond James Analyst forecast on PRAX
Raymond James
Raymond James
$815
Buy
137.96%
Upside
Initiated
04/08/26
Praxis Precision initiated with a Strong Buy at Raymond JamesPraxis Precision initiated with a Strong Buy at Raymond James
H.C. Wainwright Analyst forecast on PRAX
H.C. Wainwright
H.C. Wainwright
$1,245
Buy
263.50%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Adagene (NASDAQ: ADAG), Caribou Biosciences (NASDAQ: CRBU) and Praxis Precision Medicines (NASDAQ: PRAX)
Wolfe Research Analyst forecast on PRAX
Wolfe Research
Wolfe Research
$500
Buy
45.99%
Upside
Reiterated
04/06/26
Praxis: EMBRAVE Data Validate Elsunersen and De‑Risk Pipeline, Supporting Buy Rating on Favorable Risk‑Reward
Guggenheim Analyst forecast on PRAX
Guggenheim
Guggenheim
$800
Buy
133.58%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX), PepGen Inc. (NASDAQ: PEPG) and Omeros (NASDAQ: OMER)
Jefferies Analyst forecast on PRAX
Jefferies
Jefferies
$525
Buy
53.28%
Upside
Reiterated
03/31/26
Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
Truist Financial Analyst forecast on PRAX
Truist Financial
Truist Financial
$700
Buy
104.38%
Upside
Reiterated
03/12/26
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (NASDAQ: SPRY), BillionToOne, Inc. Class A (NASDAQ: BLLN) and Praxis Precision Medicines (NASDAQ: PRAX)
Wedbush
$95$130
Sell
-62.04%
Downside
Reiterated
02/20/26
Analysts Conflicted on These Healthcare Names: US Physical Therapy (NYSE: USPH), Travere Therapeutics (NASDAQ: TVTX) and Praxis Precision Medicines (NASDAQ: PRAX)
Robert W. Baird Analyst forecast on PRAX
Robert W. Baird
Robert W. Baird
$275$433
Buy
26.42%
Upside
Reiterated
02/20/26
Praxis Precision price target raised to $433 from $275 at BairdPraxis Precision price target raised to $433 from $275 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Praxis Precision Medicines

3 Months
xxx
Success Rate
11/11 ratings generated profit
100%
Average Return
+55.05%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +55.05% per trade.
1 Year
Yatin SunejaGuggenheim
Success Rate
10/11 ratings generated profit
91%
Average Return
+228.85%
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +228.85% per trade.
2 Years
xxx
Success Rate
21/21 ratings generated profit
100%
Average Return
+490.32%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +490.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRAX Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
32
27
30
23
27
Buy
23
24
21
8
8
Hold
0
0
2
2
4
Sell
0
0
0
0
0
Strong Sell
1
2
3
2
1
total
56
53
56
35
40
In the current month, PRAX has received 35 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. PRAX average Analyst price target in the past 3 months is 625.31.
Each month's total comprises the sum of three months' worth of ratings.

PRAX Financial Forecast

PRAX Earnings Forecast

Next quarter’s earnings estimate for PRAX is -$3.57 with a range of -$5.23 to -$2.87. The previous quarter’s EPS was -$3.50. PRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRAX is -$3.57 with a range of -$5.23 to -$2.87. The previous quarter’s EPS was -$3.50. PRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.

PRAX Sales Forecast

Next quarter’s sales forecast for PRAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.
Next quarter’s sales forecast for PRAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.

PRAX Stock Forecast FAQ

What is PRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Praxis Precision Medicines’s 12-month average price target is 625.31.
    What is PRAX’s upside potential, based on the analysts’ average price target?
    Praxis Precision Medicines has 82.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRAX a Buy, Sell or Hold?
          Praxis Precision Medicines has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Praxis Precision Medicines’s price target?
            The average price target for Praxis Precision Medicines is 625.31. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1,245.00 ,the lowest forecast is $130.00. The average price target represents 82.57% Increase from the current price of $342.5.
              What do analysts say about Praxis Precision Medicines?
              Praxis Precision Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of PRAX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.